Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,702
  • Shares Outstanding, K 36,650
  • Annual Sales, $ 40 K
  • Annual Income, $ -8,810 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.31
  • Price/Sales 30.24
  • Price/Cash Flow N/A
  • Price/Book 4.13
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings $-0.08 on 11/13/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8550 +3.11%
on 02/26/26
1.0800 -18.37%
on 02/02/26
-0.0175 (-1.95%)
since 01/27/26
3-Month
0.7900 +11.59%
on 12/29/25
1.2500 -29.47%
on 01/09/26
-0.0046 (-0.52%)
since 11/26/25
52-Week
0.7006 +25.83%
on 11/14/25
1.4500 -39.20%
on 09/19/25
-0.1183 (-11.83%)
since 02/27/25

Most Recent Stories

More News
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed...

RNXT : 0.8816 (+1.92%)
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

MOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.8816 (+1.92%)
RenovoRx Establishes RenovoCath® Medical Advisory Board

MOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.8816 (+1.92%)
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.8816 (+1.92%)
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.8816 (+1.92%)
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.8816 (+1.92%)
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies,...

RNXT : 0.8816 (+1.92%)
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

MOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT)  (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.8816 (+1.92%)
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows...

RNXT : 0.8816 (+1.92%)
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.8816 (+1.92%)

Business Summary

RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.

See More

Key Turning Points

3rd Resistance Point 0.9698
2nd Resistance Point 0.9449
1st Resistance Point 0.9049
Last Price 0.8816
1st Support Level 0.8400
2nd Support Level 0.8151
3rd Support Level 0.7751

See More

52-Week High 1.4500
Fibonacci 61.8% 1.1637
Fibonacci 50% 1.0753
Fibonacci 38.2% 0.9869
Last Price 0.8816
52-Week Low 0.7006

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar